.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Moodys
Fuji
Express Scripts
Teva
Cantor Fitzgerald
UBS
Cerilliant
Merck
Daiichi Sankyo

Generated: June 25, 2017

DrugPatentWatch Database Preview

Lovastatin - Generic Drug Details

« Back to Dashboard

What are the generic sources for lovastatin and what is the scope of lovastatin patent protection?

Lovastatin
is the generic ingredient in three branded drugs marketed by Sandoz, Covis Pharma Bv, Sun Pharm Inds, Actavis Elizabeth, Mylan, Merck, Apotex Inc, Teva, Carlsbad, and Lupin, and is included in twelve NDAs. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lovastatin has thirty-three patent family members in twelve countries.

There are thirty-three drug master file entries for lovastatin. Forty suppliers are listed for this compound.

Summary for Generic Name: lovastatin

Tradenames:3
Patents:4
Applicants:10
NDAs:12
Drug Master File Entries: see list33
Suppliers / Packagers: see list40
Bulk Api Vendors: see list66
Clinical Trials: see list58
Patent Applications: see list6,339
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:lovastatin at DailyMed

Pharmacology for Ingredient: lovastatin

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm Inds
LOVASTATIN
lovastatin
TABLET;ORAL077520-001Apr 14, 2006ABRXNoNo► Subscribe► Subscribe
Carlsbad
LOVASTATIN
lovastatin
TABLET;ORAL075991-001Jun 5, 2002ABRXNoNo► Subscribe► Subscribe
Sun Pharm Inds
LOVASTATIN
lovastatin
TABLET;ORAL077520-003Apr 14, 2006ABRXNoNo► Subscribe► Subscribe
Mylan
LOVASTATIN
lovastatin
TABLET;ORAL075935-002Dec 17, 2001DISCNNoNo► Subscribe► Subscribe
Teva
LOVASTATIN
lovastatin
TABLET;ORAL075551-003Dec 17, 2001ABRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: lovastatin

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck
MEVACOR
lovastatin
TABLET;ORAL019643-002Mar 28, 19914,231,938*PED► Subscribe
Merck
MEVACOR
lovastatin
TABLET;ORAL019643-004Dec 14, 19884,231,938*PED► Subscribe
Merck
MEVACOR
lovastatin
TABLET;ORAL019643-003Aug 31, 19874,231,938*PED► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: lovastatin

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,679,534HMG-CoA reductase inhibitor extended release formulation► Subscribe
6,440,387 Methods for determining risk of Alzheimer's disease► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: lovastatin

Country Document Number Estimated Expiration
Australia2004201520► Subscribe
Australia737962► Subscribe
Australia759257► Subscribe
Japan2002508311► Subscribe
Germany10085183► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Fuji
Healthtrust
Deloitte
Colorcon
Mallinckrodt
Farmers Insurance
Queensland Health
Accenture
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot